Nuance Pharma

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
ensifentrine(Ohtuvayre)
Approved
PDE3/PDE4Small molecule
Chronic Obstructive Pulmonary Disease

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
ensifentrine · OhtuvayrePhase 2Pulmonary Disease, Chronic Obstructive, COPD
Est. primary completion 2027-03-01 · NCT05270525 · CT.gov ↗
What to watch
September 2027 (1)
ensifentrine · OhtuvayrePhase 2Non-cystic Fibrosis Bronchiectasis
Est. primary completion 2027-09-24 · NCT06559150 · CT.gov ↗
What to watch
2029 (1)
April 2029 (1)
ensifentrine · OhtuvayrePhase 3Pulmonary Disease, Chronic Obstructive
Est. primary completion 2029-04-29 · NCT07874815 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

January 2026Filing acceptedensifentrineChina's NMPA accepts Nuance Pharma's NDA for Ohtuvayre (ensifentrine) in COPD
CN, NMPA · Nuance Pharma · Source ↗

Financial reports

No financial reports recorded.